Abstract. The present study aimed to investigate the expression of microRNA-495 (miR-495) in non-small cell lung cancer (NSCLC) tissues and cells, as well as its function on the proliferation of lung cancer cells. The expression of miR-495 in 122 pairs of NSCLC tissues and matched paracarcinoma tissues, as well as in human lung cancer cell lines (A549, H460, H1650, H520 and SK-MES-1) and the normal human pulmonary bronchial epithelial cell line 16HBE was determined using reverse transcription quantitative polymerase chain reaction (RT-qPCR). As predicted by bioinformatics analysis, high mobility group A2 (HMGA2) may be a potential target gene of miR-495. In addition, the regulatory function of miR-495 on its target gene HMGA2 was evaluated using a dual-luciferase reporter assay, RT-qPCR and western blotting. Furthermore, the effect of miR-495 on the proliferation of A549 lung cancer cells was investigated using a Cell Counting Kit-8 (CCK-8) assay. The results demonstrated that the expression of miR-495 in NSCLC tissues and cells was significantly downregulated compared with the control. In addition, downregulated expression of miR-495 was associated with tumor differentiation, lymph node metastasis and tumor, node and metastasis staging. Additionally, a dual-luciferase reporter assay revealed that miR-495 could directly associate with the 3'-untranslated region of HMGA2. Upregulated expression of miR-495 significantly downregulated the mRNA and protein expression levels of HMGA2 in A549 cells. Furthermore, the results of CCK-8 assay revealed that upregulated expression of miR-495 significantly suppressed the proliferation of A549 cells; HMGA2 overexpression reversed this inhibition. In summary, the findings of the present study demonstrated that miR-495 was downregulated in NSCLC tissues and cells. In addition, miR-495 suppressed the proliferation of lung cancer cells by directly targeting HMGA2.

Introduction

Lung cancer is one of the most common types of life-threatening malignancies worldwide (1). Non-small cell lung cancer (NSCLC) accounts for 80-85% of cases in lung cancer (2). Surgery-oriented multimodality therapy is the most effective method for the treatment of lung cancer (3); however, there are no symptoms in most patients with lung cancer at early-stage of this disease, and majority of the patients are diagnosed at the moderate to advanced stage, which has deprived them from the opportunity of radical surgery (4). Recently, molecular therapy against the targeting of genes has become a promising treatment of tumors (5). In summary, investigating the mechanisms underlying lung cancer and identifying the potential molecular targets are important in the treatment of this disease.

MicroRNAs (miRNAs) are a class of endogenous and highly conserved single-stranded non-coding small RNAs consisting of 18-22 nucleotides. MiRNAs can bind with the 3'-untranslated region (UTR) of their downstream target gene, consequently degrading mRNA or inhibiting translation at the post-transcription level. Each miRNA regulates numerous target genes; while a specific target mRNA can also be regulated by several miRNAs at the same time (6). They function in a complex regulatory network and act as oncogene or tumor suppressor during the development of tumors (7,8). Recent research has revealed that miR-495 functions as tumor suppressor gene in the majority of solid tumors, including gastric cancer (9), esophageal cancer (10), colorectal cancer (11), renal cell carcinoma (12) and bladder cancer (13); however, the underlying mechanism remains unknown. To investigate the regulatory function of miR-495 in NSCLC, the expression levels of miR-495 in NSCLC and paracarcinoma tissues, as well as in NSCLC cells and normal pulmonary bronchial epithelial cells were compared in the present study. In addition, the association between the expression of miR-495 and the clinicopathological features of patients with NSCLC was evaluated. A549 lung cancer cells were transfected with miR-495 mimics; the effects of miR-495 overexpression on the proliferation of A549 cells were revealed. Additionally, whether high mobility group A2 (HMGA2) is a potential

Correspondence to: Dr Haiwen Wang, Department of Cardio-Thoracic Surgery, Weihai Central Hospital, 3 Mishan East Road West, Wendeng, Weihai, Shandong 264400, P.R. China E-mail: wanghaiwenxxwk@yeah.net

Key words: microRNA-495, lung cancer, high mobility group AT-hook 2, proliferation
target gene of miR-495 was investigated via bioinformatics analysis in the present study.

Materials and methods

Patient samples. A total of 122 pairs of NSCLC and matched paracarcinoma samples (>5 cm from tumor margin; 80 males and 42 females; aged 45-77 years old) were obtained via surgery in Weihai Central Hospital (Weihai, China) from June 2014 to June 2016. The tissues were snap-frozen in liquid nitrogen within 30 min following surgery and stored at -80°C until further use. None of the patients received chemotherapy or radiotherapy prior to surgery. In addition, no malignancy in other organs was reported. miR-495 expression was categorized into low and high groups according to the mean value. All pathological sections were examined and verified by two senior pathologists. The clinical features of patients were presented in Table I.

TNM staging was carried out according to the 7th edition of the Union for International Cancer Control (UICC) staging Committee TNM staging standards (14). Informed consent was obtained from all patients. The present study was approved by the Medical Ethics Committee of Weihai Central Hospital.

Cell culture. Human NSCLC cell lines A549, H460, H1650, H520 and SK-MES-1, as well as the normal human pulmonary bronchial epithelial cell line 16HBE were purchased from the American Type Culture Collection (Manassas, VA, USA). Cells were cultured in Roswell Park Memorial Institute 1640 medium (RPMI-1640) (HyClone; GE Healthcare, Chicago, IL, USA) containing 10% fetal bovine serum (FBS, Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) at 37°C in a humidified atmosphere of 5% CO₂. Cell lines were selected for subsequent experiments.

Reverse transcription-quantitative polymerase chain reaction (RT-qPCR). Total RNA from tissues or cells was extracted using TRIzol® reagent (Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA) according to the manufacturer's protocols. The purity of the extracted RNA was determined using an ultraviolet spectrophotometer. cDNA was synthesized using a PrimeScript RT reagent kit (Promega Corporation), and the concentration of the cDNA was measured using a plate reader.

Bioinformatic prediction and dual-luciferase reporter assay. HMGA2 was identified as the potential direct target of miR-495 via the bioinformatics database miRanda version August 2010 Release (available at: www.microrna.org). The wild-type (wt) pmirGLO-HMGA2-wtUTR and mutant (mut) pmirGLO-HMGA2-mtUTR plasmids were synthesized by Shanghai GenePharma Co., Ltd. A549 cells (5x10⁶ cells/well) were plated onto 6-well plates. Then, 100 ng pmirGLO-HMGA2-wtUTR or pmirGLO-HMGA2-mtUTR plasmids were used to co-transfect A549 cells with 50 nM miR-495 mimics or mimics-NC using Lipofectamine® 2000 (Invitrogen; Thermo Fisher Scientific, Inc.). Cells were harvested 24 h post-transfection. Luciferase activity was evaluated 48 h post-transfection using a Dual-Luciferase® Reporter Assay (Promega Corporation), and the levels of firefly luciferase activity were normalized to that of Renilla luciferase.

Western blotting. Transfected A549 cells were collected and washed with PBS for three times. The total protein of cells was extracted with the protein lysis buffer (Cell Signaling Technology Inc., Danvers, MA, USA), and the concentration of protein was determined using a bicinchoninic acid assay. Protein samples (40 µg) were separated on a 10% SDS-PAGE gel for 30 min and transferred to polyvinylidene difluoride membranes. Then, the membranes were blocked in tris-buffered-saline-Tween-20 (TBST; containing 0.1% Tween-20) with 5% skimmed milk for 2 h at room temperature and incubated with primary antibodies against HMGA2 (1:1,000; Santa Cruz Biotechnology, Inc., Dallas, TX, USA; cat. no. sc-130024) and β-actin (1:2,000; Santa Cruz Biotechnology, Inc., Dallas, TX, USA; cat. no. sc-130065) at 4°C overnight with agitation. Following washing, the membranes were incubated with goat anti-mouse horseradish peroxidase-conjugated secondary antibody (1:2,000; Santa Cruz Biotechnology, Inc.; sc-516102)
at room temperature for 2 h. Signals were visualized using an enhanced chemiluminescence luminescent reagent (cat. no. sw2030; Beijing Solarbio Science & Technology Co., Ltd., Beijing, China) and were developed using a gel imaging system. β-actin was used as the internal reference. Bands were analyzed with Image J software (version 1.51j8; National Institutes of Health, Bethesda, MD, USA).

Statistical analysis. SPSS 19.0 software (IBM Corp., Armonk, NY, USA) was employed to perform statistical analysis. Data were presented as the mean ± standard deviation and analyzed using a Student's t-test or analysis of variance (ANOVA). A Student-Newman-Keuls test was used as a post-hoc test following ANOVA. Enumeration data were compared using a χ² test. All experiments were repeated three times. P<0.05 was considered to indicate a statistically significant difference.

Results

Expression of miR-495 is downregulated in NSCLC tissues and cells. The expression levels of miR-495 were significantly downregulated in NSCLC tissues compared with in matched paracarcinoma tissues (P<0.05; Fig. 1A). Furthermore, the expression of miR-495 was also significantly reduced in NSCLC cell lines A549, H460, H1650, H520 and SK-MES-1 compared with in the normal pulmonary bronchial epithelial cell line 16HBE (P<0.05; Fig. 1B). In addition, the relative expression levels of miR-495 in A549 cells were the lowest. Therefore, A549 was selected for further cytological study to ectopically overexpress miR-495.

HMGA2 is a direct target gene of miR-495. HMGA2 was predicted to be a potential direct target gene of miR-495.

Table I. Associations between miR-495 expression and the clinicopathological characteristics of patients with non-small cell lung cancer.

| Clinicopathological features | n | Low expression | High expression | P-value |
|-----------------------------|---|----------------|----------------|---------|
|                            | n | Low expression | High expression |         |
| Gender                      |   |                |                |         |
| Male                        | 80| 40 (50.00)     | 40 (50.00)     | 0.316   |
| Female                      | 42| 25 (59.52)     | 17 (40.48)     |         |
| Age (year)                  |   |                |                |         |
| >60                         | 72| 42 (58.33)     | 30 (41.67)     | 0.179   |
| ≤60                         | 50| 23 (46.00)     | 27 (54.00)     |         |
| Tumor size                  |   |                |                |         |
| >5 cm                       | 53| 31 (58.49)     | 22 (41.51)     | 0.312   |
| ≤5 cm                       | 69| 34 (49.28)     | 35 (50.72)     |         |
| Tumor differentiation       |   |                |                |         |
| Well + Moderate             | 77| 34 (44.16)     | 43 (55.84)     | 0.008   |
| Poorly                      | 45| 31 (68.89)     | 14 (31.11)     |         |
| TNM stage                   |   |                |                |         |
| I + II                      | 84| 39 (46.43)     | 45 (53.57)     | 0.024   |
| III                         | 38| 26 (68.42)     | 12 (31.58)     |         |
| Smoking                     |   |                |                |         |
| Yes                         | 51| 30 (58.82)     | 21 (41.18)     | 0.298   |
| No                          | 71| 35 (49.30)     | 36 (50.70)     |         |
| Lymphatic metastasis        |   |                |                |         |
| Yes                         | 72| 46 (63.89)     | 26 (36.11)     | 0.005   |
| No                          | 50| 19 (38.00)     | 31 (62.00)     |         |
| Pathology classification    |   |                |                |         |
| Squamous cell carcinoma     | 54| 24 (44.44)     | 30 (55.56)     | 0.081   |
| Adenocarcinoma              | 68| 41 (60.29)     | 27 (39.71)     |         |

P<0.05. miR, microRNA; TNM, tumor, node and metastasis.

Expression of miR-495 is associated with the clinicopathological parameters of patients with NSCLC. The mean miR-495 expression levels in all patients were used as the threshold to divide the patients into miR-495 high and low expression groups. Downregulated expression of miR-495 was associated with tumor differentiation, lymph node metastasis and clinical stage (P<0.05; Table I), but was not associated with age, sex, tumor size, smoking and pathological classification (Table I).
using the target gene prediction database miRanda and gene functional analysis. In addition, there were complementary binding sites to the seed sequence of miR-495 in the 3′-UTR of HMGA2 (Fig. 2A). To further investigate whether HMGA2 was the direct regulatory target gene of miR-495, A549 cells were co-transfected with miR-495 mimics or mimics-NC, and pmirGLO-HMGA2-wtUTR or pmirGLO-HMGA2-mtUTR. The results of the dual-luciferase reporter assay revealed that the luciferase activity of cells in the miR-495mimics + pmirGLO-HMGA2-wtUTR group was significantly reduced compared with that of the mimics-NC + pmirGLO-HMGA2-wtUTR group (Fig. 2B). Additionally, no significant difference was observed between cells in miR-495mimics + pmirGLO-HMGA2-mt group and the mimics-NC + pmirGLO-HMGA2-wtUTR group (P>0.05; Fig. 2B). These results indicated that miR-495 could specifically bind to the 3′-UTR of HMGA2; however, this effect was not detected in the presence of 3′-UTR-mutated HMGA2, suggesting that HMGA2 may be the direct target of miR-495. MiR-495 inhibits the proliferation of A549 cells in a HMGA2-dependant manner. The expression levels of miR-495 in A549 cells in the miR-495 mimics and miR-495 mimics + HMGA2 groups were significantly upregulated compared with in the mimic-NC group (P<0.001; Fig. 3B-D). Furthermore, the expression of HMGA2 in the miR-495 mimics + HMGA2 group was significantly upregulated compared with in the miR-495 mimics group (P<0.001; Fig. 3B-D). In addition, the results of the CCK-8 assay revealed that upregulated expression of miR-495 could significantly inhibit the proliferation of A549 cells compared with the control (P<0.01), while HMGA2 overexpression could significantly reversed this inhibition (P<0.01; Fig. 3E). The above results show that miR-495 inhibits the proliferation of A549 cells in a HMGA2-dependant manner.

Discussion

Lung cancer is a frequently-occurring malignancy, and its initiation and development are complex processes involving numerous genetic alterations (16); however, the molecular mechanisms underlying this disease remain unclear. Recently, the roles of miRNA in numerous diseases have attracted increasing attention with advances in of epigenetic research (17). Aberrant expression of miRNA in the majority of malignancies has been revealed; miRNAs serve an indispensable role in the initiation and development of malignancies (18,19).

MiR-495 is a novel miRNA that is located in chromosome 14q32.31 (20). It serves an important role in cell proliferation, apoptosis, and the immune and inflammatory responses (21). It has been revealed that aberrant expression of miR-495 was associated with tumor cell proliferation, apoptosis and chemoresistance (22). In addition, miR-495 functioned as tumor suppressor in the majority of solid tumors (9-13); however, the expression of miR-495 was upregulated in some solid tumors, including hepatocellular carcinoma (23) and breast cancer (24), and thus may be considered as an oncogene. In the present study, the expression levels of miR-495 in NSCLC and matched paracarcinoma tissues, as well as in human lung cancer and normal human pulmonary bronchial
epithelial cells were compared. The results revealed that miR-495 expression in NSCLC tissues and cells was significantly downregulated. In addition, to investigate the effects of miR-495 on the proliferation of lung cancer cells, miR-495 mimics were successfully transfected into A549 cells. Thus, A549 cells overexpressing miR-495 were established; overexpression of miR-495 significantly inhibited the proliferation of A549 cells, indicating that miR-495 could function as a tumor suppressor gene in NSCLC.

MiRNAs may regulate numerous target genes; however, each target gene can also be regulated by several miRNAs. The role of miRNA in tumors depends on its regulatory functions on downstream target genes (25). Li et al (9) reported that miR-495 could inhibit the invasion and metastasis of gastric cancer cells in a phosphatase of regenerating liver 3-dependent manner. Mao et al (10) revealed that miR-495 could suppress the invasion of esophageal cancer by targeting protein kinase. Chu et al (26) reported that miR-495 could inhibit the proliferation and metastasis of NSCLC cells in a metastasis associated 1 family member 3-dependent manner. In the present study, the potential target gene of miR-495 was predicted to be HMGA2 using target gene prediction database miRanda and gene functional analysis; there were complementary binding sites to the seed sequence of miR-495 in the 3'-UTR of HMGA2. Additionally, a dual-luciferase reporter assay suggested that HMGA2 overexpression significantly inhibited the proliferation of lung cancer cells, indicating that miR-495 suppressed the proliferation of A549 cells, indicating that miR-495 could function as a tumor suppressor gene in NSCLC.

In the present study, the potential target gene of miR-495 was predicted to be HMGA2 using target gene prediction database miRanda and gene functional analysis; there were complementary binding sites to the seed sequence of miR-495 in the 3'-UTR of HMGA2. Additionally, a dual-luciferase reporter assay revealed that miR-495 could specifically bind to the 3'-UTR of HMGA2. Furthermore, the expression levels of HMGA2 were further determined using RT-qPCR and western blotting; upregulation of miR-495 significantly downregulated expression level of HMGA2 in NSCLC cells. Cyclin A serves an important role in promoting the mitosis and proliferation of cells; it is an important regulatory protein of the cell cycle (40). HMGA2 facilitates the progress of the cell cycle, and consequently accelerating the G2/M stage of the cell cycle. In the present study, A549 cells overexpressing HMGA2 were established; overexpression of HMGA2 significantly inhibited the proliferation of lung cancer cells (44). In the present study, A549 cells were co-transfected with miR-495 mimics and HMGA2-overexpressing plasmids. The results revealed that the expression levels of HMGA2 in the miR-495 mimics + HMGA2 group were significantly upregulated compared with the control, indicating that the inhibitory effects of miR-495 on HMGA2 expression was successfully reversed. Furthermore, the results of CCK-8 assay suggested that HMGA2 overexpression significantly reversed the inhibition of miR-495 mimics on the proliferation of A549 cells, indicating that miR-495 suppressed the proliferation of A549 cells in a HMGA2-dependent manner.

In summary, the present study revealed that miR-495 expression was downregulated in NSCLC tissues and cells.
Figure 3. MiR-495 inhibits the proliferation of A549 cells in a HMGA2-dependant manner. (A) Reverse transcription-quantitative polymerase chain reaction was used to determine the expression levels of miR-495 following transfection. The expression of miR-495 in the miR-495 mimics and miR-495 mimics + HMGA2 groups was significantly upregulated compared with in the mimic-NC group. ***P<0.001 vs. mimic-NC. (B-D) Expression of HMGA2 in A549 cells in the miR-495 mimics group was significantly downregulated compared with in the mimic-NC group. The protein expression levels of HMGA2 in the miR-495 mimics + HMGA2 groups were significantly upregulated compared with those in miR-495 mimics group. ###P<0.001 vs. miR-495 mimics; ***P<0.001 vs. mimic-NC. (E) Cell proliferation was evaluated by a Cell Counting Kit-8 assay. MiR-495 inhibited the proliferation of A549 cells, whereas HMGA2 overexpression could reverse this inhibition. *P<0.01. MiR, microRNA; HMGA2, high mobility group A2; NC, negative control.
Therefore, HMGA2 may be one of the direct target genes of miR-495. In addition, miR-495 could inhibit the expression of HMGA2, consequently suppressing the proliferation of lung cancer cells. The results of the present study may provide insight into the mechanisms underlying the inhibition of lung cancer cell proliferation. In conclusion, miR-495 may be considered as a potential target in the treatment of lung cancer via gene therapy in the future.

Acknowledgements

Not applicable.

Funding

No funding was received.

Availability of data and materials

The analyzed data sets generated during the present study are available from the corresponding author on reasonable request. All authors have read and approved the manuscript.

Authors’ contributions

HW designed the experiments. JS, YQ and TS performed the experiments. JS and HW analyzed the data. JS wrote the manuscript. HW designed the experiments. JS, YQ and TS performed the experiments. JS and HW analyzed the data. JS wrote the manuscript.

Ethics approval and consent to participate

The present study was approved by the Medical Ethics Committee of Weihai Central Hospital (Weihai, China). Informed consent was obtained from all patients.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin 60: 277-300, 2010.
2. Ridge CA, Mcerlean AM and Ginsberg MS: Epidemiology of lung cancer. Semin Intervent Radiol 30: 93-98, 2013.
3. Wakelee H, Kelly K and Edelman MJ: 50 Years of progress in the systemic therapy of non-small cell lung cancer. Semin Intervent Radiol 30: 93-98, 2013.
4. Zhan P, Qian Q and Yu LK: Prognostic value of COX-2 expression in patients with non-small cell lung cancer: A systematic review and meta-analysis. J Thorac Dis 5: 40-47, 2013.
5. Sheng M, Zhao Y, Wang F, Li S, Wang X, Shou T, Luo Y and Tang W: Targeted drugs for unsselected patients with advanced non-small-cell lung cancer: A network meta-analysis. J Thorac Dis 5: 98-115, 2013.
6. Acunzo M and Croce CM: MicroRNA in cancer and cachexia—a mini-review. J Infect Dis 212 (Suppl 1): S74-S77, 2015.
7. Farazi TA, Spitzer JI, Morozov P and Tuschi T: miRNAs in human cancer. J Pathol 223: 102-115, 2011.
8. Sorel O and Dewals BG: MicroRNAs in large herpesvirus DNA genomes: Recent advances. Biomol Concepts 7: 229-239, 2016.
9. Li Z, Zhang G, Li D, Jie Z, Chen H, Xiong J, Liu Y, Cao Y, Jiang M, Le Z and Tan S: Methylated-associated silencing of miR-495 inhibit the migration and invasion of human gastric cancer cells by directly targeting PRL-3. Biochem Biophys Res Commun 456: 344-350, 2015.
10. Mao Y, Li L, Liu J, Wang L and Zhou Y: MiR-495 inhibits esophageal squamous cell carcinoma progression by targeting Akt1. Oncotarget 7: 5123-5126, 2016.
11. Yan L, Yao J and Qiu J: miRNA-495 suppresses proliferation and migration of colorectal cancer cells by targeting FAM3D. Biomed Pharmacother 96: 974-981, 2017.
12. Lu Y, Liu WG, Lu JH, Liu ZJ, Li HB, Liu GJ, She HY, Li GY and Shi XH: LncRNA UCA1 promotes renal cell carcinoma proliferation through epigenetically repressing p21 expression and negatively regulating miR-495. Tumour Biol 39: 10104283/20161632, 2017.
13. Tan M, Mu X, Liu Z, Tao L, Wang J, Ge J and Qiu J: microRNA-495 promotes bladder cancer cell growth and invasion by targeting phosphatase and tensin homolog. Biochem Biophys Res Commun 483: 867-873, 2017.
14. Wang J, Wu N, Zheng Q, Feng Y, Yan S, Ly C, Li S, Wang Y and Yang Y: Evaluation of the 7th edition of the TNM classification for lung cancer at a single institution. J Cancer Res Clin Oncol 140: 1189-1195, 2014.
15. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25: 402-408, 2001.
16. Mehta A, Dobersch S, Romero-olmedo AJ and Barreto G: Epigenetics in lung cancer diagnosis and therapy. Cancer Metastasis Rev 34: 229-241, 2015.
17. Hesse M and Arenz C: MicroRNA maturation and human disease. Methods Mol Biol 1095: 11-25, 2014.
18. Salido-Guadarrama I, Romero-Cordoba S, Peralta-Zaragoza O, Hidalgo-Miranda A and Rodriguez-Dorantes M: MicroRNAs transported by exosomes in body fluids as mediators of intercellular communication in cancer. Onco Targets Ther 7: 1327-1338, 2014.
19. Wang Z, Yao H, Lin S, Zhu X, Shen Z, Lu G, Poon WS, Xie D, Lin MC and Kung HF: Transcriptional and epigenetic regulation of human microRNAs. Cancer Lett 331: 1-10, 2013.
20. Li X, Song Y, Liu D, Zhao J, Xu J, Ren J, Hu Y, Wang Z, Hou Y and Zhao G: MiR-495 promotes senescence of mesenchymal stem cells by targeting Brm-1. Cell Physiol Biochem 42: 780-796, 2017.
21. Zhang X, Yang Y and Feng Z: Suppression of microRNA-495 alleviates high-glucose-induced retinal ganglion cell apoptosis by regulating Notch/PTEN/Akt signaling. Biomed Pharmacother 106: 923-929, 2018.
22. Bai Z, Wang J, Wang T, Li Y, Zhao X, Wu G, Yang Y, Deng W and Zhang Z: The MiR-495/Annexin A3/P53 axis inhibits the invasion and EMT of colorectal cancer cells. Cell Physiol Biochem 44: 1882-1895, 2017.
23. Yang H, Cho ME, Li TW, Peng H, Ko KS, Mato JM and Lu SC: MicroRNAs regulate methionine adenosyltransferase 1A expression in hepatocellular carcinoma. J Clin Invest 123: 285-298, 2013.
24. Hwang-Verslues WW, Chang PH, Wei PC, Yang CY, Huang CK, Kuo WH, Shew JY, Chang KJ, Lee EY and Lee WH: miR-495 is upregulated by E12/E47 in breast cancer stem cells, and promotes oncogenesis and hypoxia resistance via downregulation of E-cadherin and REDD1. Oncogene 30: 2463-2474, 2011.
25. Liu B, Li J and Cairns MJ: Identifying miRNAs, targets and functions. Brief Bioinform 15: 1-19, 2014.
26. Chu H, Chen X, Wang H, Du Y, Wang Y, Zang W, Li P, Li J, Chang J, Zhao G and Zhang G: MiR-495 regulates proliferation and migration in NSCLC by targeting MTAV3. Tumour Biol 35: 3487-3494, 2014.
27. Yang F, Zhao L, Mei D, Jiang L, Geng C, Li Q, Yao X, Liu Y, Kong Y and Cao J: HMGA2 plays an important role in Cr(VI)-induced autophagy. Int J Cancer 141: 986-997, 2017.
28. Busch B, Bley N, Müller S, Gläß M, Missik D, Lezderer M, Vetter M, Strauß HG, Thomsen C and Hüttelmaier S: The oncogenic triangle of HMGA2, LIN28B and IGF2BP1 antagonizes tumor-suppressive actions of the let-7 family. Nucleic Acids Res 44: 3845-3864, 2016.
29. Jin L, Lloyd RV, Henry MR, Erickson LA, Sebo TJ, Rumilla KM and Zhang J: The diagnostic utility of combination of HMGA2 and IMP3 qRT-PCR testing in thyroid neoplasms. Appl Immunohistochem Mol Morphol 23: 36-43, 2015.
30. Yang J, Zhang Q, Dong JQ, Chang XH and He XF: Overexpression of high mobility group A2 and its correlation with microRNA-let-7 family in serous ovarian cancers. Beijing Da Xue Xue Bao Yi Xue Ban 44: 749-754, 2012 (In Chinese).
31. Zhu C, Li J, Cheng G, Zhou H, Tao L, Cai H, Li P, Cao Q, Ju X, Meng X, et al: miR-154 inhibits EMT by targeting HMGA2 in prostate cancer cells. Mol Cell Biochem 379: 69-75, 2013.
32. Zou Q, Xiong L, Yang Z, Lv F, Yang L, and Miao X: Expression levels of HMGA2 and CD9 and its clinicopathological significances in the benign and malignant lesions of the gallbladder. World J Surg Oncol 10: 92, 2012.
33. Liu Q, Lv GD, Qin X, Gen YH, Zheng ST, Liu T and Lu XM: Role of microRNA let-7 and effect to HMGA2 in esophageal squamous cell carcinoma. Mol Biol Rep 39: 1239-1246, 2012.
34. Ding X, Wang Y, Ma X, Guo H, Yan X, Chi Q, Li J, Hou Y and Wang C: Expression of HMGA2 in bladder cancer and its association with epithelial-to-mesenchymal transition. Cell Prolif 47: 146-151, 2014.
35. Meyer B, Loechcke S, Schultz A, Weigel T, Sandkamp M, Goldmann T, Vollmer E and Bullerdiek J: HMGA2 overexpression in non-small cell lung cancer. Mol Carcinog 46: 503-511, 2007.
36. Kong D, Su G, Zha L, Zhang H, Xiang J, Xu W, Tang Y and Wang Z: Coexpression of HMGA2 and Oct4 predicts an unfavorable prognosis in human gastric cancer. Med Oncol 31: 130, 2014.
37. Fusco A and Fedele M: Roles of HMGA proteins in cancer. Nat Rev Cancer 7: 899-910, 2007.
38. Denechaud PD, Fujas L and Giralt A: E2F1, a novel regulator of metabolism. Front Endocrinol (Lausanne) 8: 311, 2017.
39. Fedele M, Pierantoni GM, Visone R and Fusco A: E2F1 activation is responsible for pituitary adenomas induced by HMGA2 gene overexpression. Cell Div 1: 17, 2006.
40. Loukil A, Cheung CT, Bendris N, Lemmers B, Peter M and Blanchard JM: Cyclin A2: At the crossroads of cell cycle and cell invasion. World J Biol Chem 6: 346-350, 2015.
41. Tessari MA, Gostissa M, Altamura S, Sgarra R, Rustighi A, Salvagno C, Caretti G, Imbriano C, Mantovani R, Del Sal G, et al: Transcriptional activation of the cyclin A gene by the architectural transcription factor HMGA2. Mol Cell Biol 23: 9104-9116, 2003.
42. D'Angelo D, Esposito F and Fusco A: Epigenetic mechanisms leading to overexpression of HMGA proteins in human pituitary adenomas. Front Med (Lausanne) 2: 39, 2015.
43. Morishita A, Zaidi MR, Mitoro A, Sankarasharma D, Szabolcs M, Okada Y, D'Armiento J and Chada K: HMGA2 is a driver of tumor metastasis. Cancer Res 73: 4289-4299, 2013.
44. Di Cello F, Hillion J, Hristov A, Wood LJ, Mukherjee M, Schulenfrei A, Kowalski J, Bhattacharya R, Ashfaq R and Resar LM: HMGA2 participates in transformation in human lung cancer. Mol Cancer Res 6: 743-750, 2008.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.